Safety & Efficacy of Treprostinil in Ischemia & Reperfusion Injury in

Status Completed

Clinical Trial Summary

The overall purpose of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of a five-days post-operative course of Treprostinil in liver transplant patients. The hypothesis of this study is that Treprostinil can be safely administered post-operatively in liver transplant patients. Once safety is documented future studies will address its ability to ameliorate or prevent reperfusion mediated dysfunction of the liver graft and thereby reduce morbidity, leading to shorter hospital stays as compared to historical controls.

Clinical Trial Description

Prostaglandin-class drugs, including prostacyclin and its analogs, could represent an important advance toward the goal of reducing transplant related morbidity, mortality and associated costs by minimizing the effect of ischemia and re perfusion injury of the liver graft. Additionally, the reduction in serum creatinine and reduced need for post operative dialysis observed in some studies has implications in protecting the kidneys from the nephrotoxic affects of the immunosuppressant agents, especially during the early post-operative period. Routine use of prostaglandins (PGE1 and PGI2), however, was limited by its instability and short half life. Treprostinil, as a prostanoid (prostacyclin analog), is expected to facilitate restoration of the blood supply to the revascularized graft and provide the well-characterized protective effects of this class of compounds in liver transplant patients. Treprostinil has the advantage of a longer elimination half-life than other prostanoids previously tested in these patients. Treprostinil is expected to significantly protect the graft from ischemia and re perfusion injury. This is a pilot study to evaluate the safety, pharmacokinetics and preliminary efficacy of Treprostinil in orthotopic liver transplant patients as a first step to evaluate its use in prevention of ischemia and reperfusion injury of the grafted liver. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01481974
Study type	Interventional
Source	University of Pittsburgh
Contact
Status	Completed
Phase	Phase 1
Start date	December 2012
Completion date	November 24, 2019

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06369350` - Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion	Early Phase 1
Withdrawn	`NCT04388761` - Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)	Phase 1
Completed	`NCT00987974` - Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury	Phase 4
Recruiting	`NCT04750616` - NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial	Phase 2
Recruiting	`NCT05992259` - Auricular Vagus Stimulation and STEMI	N/A
Completed	`NCT04493983` - Role of Oxidative Stress in Ovarian Tissue After CO2-pneumoperitoneum Application-induced I/R	N/A
Completed	`NCT03510793` - Microcirculation and Anesthesia in Vascular Surgery
Recruiting	`NCT02845154` - Intermittent Portal and Graft Purge in Living Donor Liver Transplantation	N/A
Terminated	`NCT01564095` - TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion	Phase 2/Phase 3
Completed	`NCT03482544` - The Effect of Pregabalin Given Preoperatively on the Tourniquet Induced Ischemia-reperfusion	Phase 4
Not yet recruiting	`NCT05004610` - Hypertonic Lactate After Cardiac Arrest	Phase 2
Completed	`NCT04205253` - Tongue Depressor-related Ischemia-Reperfusion Injury in Tongue
Completed	`NCT03410576` - Perioperative Time Course of MMP-9 and Its Inhibitor During Carotid Artery Stenting and Carotid Endarterectomy	N/A
Completed	`NCT03743584` - Hypothermia After Cardiac Arrest - Effects on Myocardial Function and Inflammatory Response.	N/A
Recruiting	`NCT04005469` - Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation	Phase 1/Phase 2
Recruiting	`NCT04630535` - OSA as a Remote Ischemic Preconditioning in Vascular Surgery
Completed	`NCT01610401` - The Metformin-FMD Trial	Phase 4
Active, not recruiting	`NCT00876902` - YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation	Phase 2
Completed	`NCT03541239` - Immune Modulation by Ischemic Pre-conditioning in Healthy Individuals: Intracellular Signalling in Regulatory Cells	N/A
Recruiting	`NCT05430620` - Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms